Syngene International, a global contract research, development, and manufacturing organization (CRDMO), announced that Siddharth Mittal has assumed the role of Managing Director and Chief Executive Officer of the Company, effective 1 July 2026. Siddharth succeeds Peter Bains who served as CEO and on the Board of Syngene for almost six years starting 2010 and led the company to its successful public listing in 2015.
Siddharth Mittal is a seasoned business leader with over two decades of experience in the global biopharmaceutical industry. Before being appointed as Managing Director and Chief Executive Officer of Syngene International, Mittal served as the Chief Executive Officer and Managing Director of Biocon Limited. During his tenure of thirteen years at Biocon, Siddharth held the position of Chief Financial Officer, before being appointed Managing Director and CEO. He played a pivotal role in expanding the company’s global footprint, enhancing operational efficiency, and accelerating growth across key markets. His leadership was instrumental in strengthening Biocon’s position as one of India’s leading biopharmaceutical companies.
Mittal brings with him extensive experience in leading one of India’s largest biopharmaceutical companies, making him well-equipped to navigate the rapidly evolving healthcare landscape. His proven ability to drive business transformation, expand global partnerships, and improve operational efficiency aligns closely with Syngene’s ambitions of becoming a preferred innovation partner for pharmaceutical and biotechnology companies worldwide.
His appointment also highlights a growing trend in the corporate world, where companies are choosing leaders with strong industry experience and a proven ability to execute strategy. As demand for outsourced research and manufacturing services continues to rise, Syngene is looking to strengthen its position as a trusted global partner.
For Syngene, this leadership change signals the company’s focus on innovation, sustainable growth, and expanding its presence in the global life sciences industry. Under Mittal’s leadership, the company is expected to continue building on its strengths while exploring new opportunities in an increasingly competitive market.
